Forus Triples Its Valuation to $3 Billion in Four Months

Forus, the company formerly known as Tandem, raised $150 million in a Series C announced Sept. 8, valuing it at $3 billion, according to the company. Bain Capital Ventures led the round, as it has since Forus's seed stage; Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC and SV Angel also participated.

The valuation is three times the roughly $1 billion mark Forus reached four months earlier, when it raised a $160 million Series B in May 2026 without disclosing a valuation figure at the time, according to Fierce Healthcare, which later reported the $1 billion mark independently.

What actually grew between the two rounds

Forus's usage numbers moved, but not at anything close to 3x. At the Series B, the company said its network reached providers in all 50 states covering nearly 80 percent of U.S. residential zip codes, with five of the top 10 global biopharma companies already integrated. By the Series C four months later, that had become 85 percent of zip codes and nine of the top 15 biopharma companies, a modest expansion of an already national footprint rather than the kind of step-change that usually accompanies a valuation tripling.

The problem Forus says it automates

Forus's platform uses AI agents to handle the administrative steps between a doctor writing a prescription and a patient starting treatment, including insurance prior authorization, financial-assistance enrollment and pharmacy routing, according to founder and chief executive Sahir Jaggi. The company says a prescription can require up to 15 coordination steps across separate parties, and that a third of patients prescribed high-cost or complex medications never receive a first dose.

Round	Date	Amount	Valuation
Series B	May 2026	$160 million	~$1 billion
Series C	September 2026	$150 million	$3 billion

Forus has now raised more than $300 million since its founding three years ago. Jaggi has said the company's aim is to give every prescription its own AI agent, closing the gap between a prescription being written and a patient actually filling it.

What a tripled valuation is betting on

A 3x valuation jump on a 5-point gain in zip code coverage only works if investors are pricing something other than current usage: a bet that biopharma integrations convert into per-prescription revenue faster than the network itself grows, similar to the logic behind Gimlet Labs raising $300 million five months after an undisclosed Series A. It also echoes Light's Series A pitch to investors: a network business asking to be priced on where its footprint is headed, not where it already reaches.

Forus has not disclosed revenue or a per-prescription pricing model, and it has not said how it plans to monetize the biopharma side of the network beyond calling those partners integrated. The two rounds four months apart mean the next data point that would confirm or undercut the bet, an actual revenue disclosure or a fourth round at a fourth valuation, is likely to arrive before 2026 is out.